GlycoMimetics to Present at Jefferies 2017 Global Healthcare Conference
June 05 2017 - 3:00PM
Business Wire
GlycoMimetics, Inc. (NASDAQ: GLYC) today announced that Chief
Executive Officer Rachel King will provide a company overview at
the Jefferies 2017 Global Healthcare Conference in New York City,
on Wednesday, June 7, 2017, at 2:00 p.m. ET.
To access the live webcast and subsequent archived recordings
for the presentation, please visit
the GlycoMimetics website
at www.glycomimetics.com.
About GlycoMimetics, Inc.
GlycoMimetics is a clinical-stage biotechnology company focused
on cancer and sickle cell disease. GlycoMimetics’ most advanced
drug candidate, rivipansel, a pan-selectin antagonist, is being
developed for the treatment of vaso-occlusive crisis in sickle cell
disease and is being evaluated in a Phase 3 clinical trial being
conducted by its strategic collaborator, Pfizer. GlycoMimetics'
wholly-owned drug candidate, GMI-1271, an E-selectin antagonist, is
being evaluated in an ongoing Phase 1/2 clinical trial as a
potential treatment for AML and in a Phase 1 clinical trial in
multiple myeloma. The U.S. FDA recently granted GMI-1271
Breakthrough Therapy designation for treatment of adult AML
patients with relapsed/refractory disease. GlycoMimetics has also
recently initiated a clinical trial with a third drug candidate,
GMI-1359, a combined CXCR4 and E-selectin antagonist. GlycoMimetics
is located in Rockville, MD in the BioHealth Capital Region. Learn
more at www.glycomimetics.com.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20170605005605/en/
GlycoMimetics, Inc.Investor Contact:Shari Annes,
650-888-0902sannes@annesassociates.comorMedia Contact:Jamie
Lacey-Moreira, 410-299-3310jamielacey@presscommpr.com
GlycoMimetics (NASDAQ:GLYC)
Historical Stock Chart
From Apr 2024 to May 2024
GlycoMimetics (NASDAQ:GLYC)
Historical Stock Chart
From May 2023 to May 2024